Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan 11;14(4):1039-1041.
doi: 10.1093/ckj/sfaa274. eCollection 2021 Apr.

Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects

Mariusz Kusztal  1 , Marek Myślak  2
Affiliations
Editorial

Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects

Mariusz Kusztal et al. Clin Kidney J. .

Abstract

Avoiding the use of drugs in patients with a glomerular filtration rate (GFR) <30 mL/min/1.73 m2 is due to the exclusion of this group of patients from many clinical trials. However, in view of the widespread COVID-19 pandemic and the need to treat all patients, including those with renal failure, the World Health Organization points out in the Solidarity trial the need for the inclusion some patients with kidney failure and recognizes the urgent need for trials/studies in patients with coronavirus disease 2019 (COVID-19) with lower GFR. It is well known that the therapeutic goal to treat patients with renal failure, acute kidney injury or on maintenance dialysis is complicated by pharmacokinetics, drug interactions and extracorporeal therapies. In patients with COVID-19 and impaired kidney function, the role of nephrologists is crucial in order to draw a balance between nihilism and benefits or potentially harmful effects of current available treatments. The potential use of European Medicines Agency recommended remdesivir and dexamethasone for COVID-19 among dialysis patients are discussed.

Keywords: AKI; COVID-19; SARS-CoV-2; chronic hemodialysis; dexamethasone; remdesivir.

PubMed Disclaimer

References

    1. Cheng Y, Luo R, Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829–838 - PMC - PubMed
    1. Hilbrands LB, Duivenvoorden R, Vart P. et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020; 35: 1973–1983 - PMC - PubMed
    1. Corbett RW, Blakey S, Nitsch D. et al. Epidemiology of COVID-19 in an urban dialysis center. J Am Soc Nephrol 2020; 31: 1815–1823 - PMC - PubMed
    1. Europen Medicines Agency. Treatments and vaccines for COVID-19. https://... (1 November 2020, date last accessed)
    1. European Medicines Agency. Summary of product characteristics. Veklury. ... (1 November 2020, date last accessed)

Publication types